000272598 001__ 272598
000272598 005__ 20250127091456.0
000272598 0247_ $$2pmid$$apmid:39388460
000272598 0247_ $$2doi$$a10.1371/journal.pone.0311267
000272598 0247_ $$2pmc$$apmc:PMC11466409
000272598 037__ $$aDZNE-2024-01219
000272598 041__ $$aEnglish
000272598 082__ $$a610
000272598 1001_ $$aAtemnkeng Ntam, Veronica$$b0
000272598 245__ $$aThe influence of age, gender and pharmacogenetic profiles on the perspective on medicines in the German EMPAR study
000272598 260__ $$aSan Francisco, California, US$$bPLOS$$c2024
000272598 3367_ $$2DRIVER$$aarticle
000272598 3367_ $$2DataCite$$aOutput Types/Journal article
000272598 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1729172703_2183
000272598 3367_ $$2BibTeX$$aARTICLE
000272598 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272598 3367_ $$00$$2EndNote$$aJournal Article
000272598 500__ $$aTrial registration: EMPAR was registered in the German Clinical Trials Register (DRKS) on 06 July 2018 (DRKS00013909).
000272598 520__ $$a Pharmacogenetic testing in routine care could provide benefits for patients, doctors and statutory health insurances. Therefore, the aim of the retrospective, observational study Einfluss metabolischer Profile auf die Arzneimitteltherapiesicherheit in der Routineversorgung (EMPAR) was to analyze the relationship between pharmacogenetic profiles, the risk of adverse drug reactions, and patients' perceptions of drug therapy in 10748 adult (≥18 years) participants in Germany.A questionnaire was used to assess views and beliefs about medicines and participants individual perception of sensitivity to drug therapies. The questionnaire consisted of the Beliefs about Medicines Questionnaire (BMQ)-General scales (Overuse, Harm, Benefit), the Perceived Sensitivity to Medicines (PSM), Natural Remedy, and Gene Testing scales. The influence of gender, age, study collective, genotype and phenotype of relevant pharmacogenes on participant's perception were evaluated.Overuse, PSM and Benefit scores were significantly higher among patients of the collective International Classification of Diseases and Health Related Disorders (ICD)-10 Y57.9! diagnosis, which indicates complications related to drugs, compared to the anticoagulant/antiplatelet and cholesterol-lowering drug collective. Age and gender also played a significant role in patients' perceptions, with younger patients and female participants more likely to believe in medication overuse according to the Overuse scale score compared to older and male participants. Female participants compared to male participants and the old age group compared to the young and/or middle-age subgroup, scored higher in PSM and/or Harm scales, respectively. Only a tendency of increased Harm, Overuse and PSM scores was observed in the participant group with five or more relevant actionable variants compared to subgroups with 0 up to 4 variants.In conclusion, patients' beliefs about medicines and their drug sensitivity perceptions are influenced by various factors including age, gender, previous complications with medicines, and with some tendency also pharmacogenetic profiles. The higher association with more negative views related to treatment indicates that there is a need to target the underlying issues in affected patient groups in order to improve compliance to treatment and outcomes in routine care. Trial registration: EMPAR was registered in the German Clinical Trials Register (DRKS) on 06 July 2018 (DRKS00013909).
000272598 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x0
000272598 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000272598 650_2 $$2MeSH$$aHumans
000272598 650_2 $$2MeSH$$aMale
000272598 650_2 $$2MeSH$$aFemale
000272598 650_2 $$2MeSH$$aGermany
000272598 650_2 $$2MeSH$$aMiddle Aged
000272598 650_2 $$2MeSH$$aAdult
000272598 650_2 $$2MeSH$$aAged
000272598 650_2 $$2MeSH$$aSex Factors
000272598 650_2 $$2MeSH$$aSurveys and Questionnaires
000272598 650_2 $$2MeSH$$aAge Factors
000272598 650_2 $$2MeSH$$aPharmacogenetics
000272598 650_2 $$2MeSH$$aDrug-Related Side Effects and Adverse Reactions
000272598 650_2 $$2MeSH$$aRetrospective Studies
000272598 650_2 $$2MeSH$$aYoung Adult
000272598 650_2 $$2MeSH$$aAdolescent
000272598 650_2 $$2MeSH$$aAged, 80 and over
000272598 7001_ $$00000-0003-4548-1234$$aHuebner, Tatjana$$b1
000272598 7001_ $$aSteffens, Michael$$b2
000272598 7001_ $$aRoethlein, Christoph$$b3
000272598 7001_ $$0P:(DE-2719)2810511$$aHaenisch, Britta$$b4$$udzne
000272598 7001_ $$aStingl, Julia$$b5
000272598 7001_ $$aLinder, Roland$$b6
000272598 7001_ $$00000-0002-1463-5619$$aScholl, Catharina$$b7
000272598 773__ $$0PERI:(DE-600)2267670-3$$a10.1371/journal.pone.0311267$$gVol. 19, no. 10, p. e0311267 -$$n10$$pe0311267$$tPLOS ONE$$v19$$x1932-6203$$y2024
000272598 8564_ $$uhttps://pub.dzne.de/record/272598/files/DZNE-2024-01219.pdf$$yOpenAccess
000272598 8564_ $$uhttps://pub.dzne.de/record/272598/files/DZNE-2024-01219.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272598 909CO $$ooai:pub.dzne.de:272598$$pVDB
000272598 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810511$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000272598 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x0
000272598 9141_ $$y2024
000272598 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000272598 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000272598 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-25
000272598 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-04-12T10:14:32Z
000272598 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-04-12T10:14:32Z
000272598 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-04-12T10:14:32Z
000272598 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-04-12T10:14:32Z
000272598 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-25
000272598 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-25
000272598 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000272598 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000272598 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000272598 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000272598 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-25
000272598 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2023-10-25
000272598 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000272598 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-25
000272598 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-25
000272598 9201_ $$0I:(DE-2719)1013010$$kAG Hänisch$$lPharmacoepidemiology$$x0
000272598 980__ $$ajournal
000272598 980__ $$aVDB
000272598 980__ $$aI:(DE-2719)1013010
000272598 980__ $$aUNRESTRICTED